Oral realgar-indigo naturalis formula achieved high rate of remission and survival comparable to intravenous arsenic trioxide as frontline treatment in newly diagnosed acute promyelocytic leukemia: a multi-center randomized trial APL07

被引:0
|
作者
Zhu, Hong-Hu
Wu, De-Pei
Jin, Jie
Li, Jian-Yong
Ma, Jun
Wang, Jiangxiang
Jiang, Hao
Chen, Sai-Juan
Huang, Xiao-Jun
机构
[1] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Inst Hematol, Dept Hematol,Coll Med, Hangzhou, Zhejiang, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing, Jiangsu, Peoples R China
[5] Harbin Inst Hematol & Oncol, Harbin, Peoples R China
[6] Shanghai Jiao Tong Univ, Sch Med, RuiJin Hosp, Shanghai Inst Hematol, Shanghai, Peoples R China
关键词
Indigo naturalis; arsenic trioxide; acute promyelocytic leukemia;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
41
引用
收藏
页码:20 / 21
页数:2
相关论文
共 2 条
  • [1] Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial
    Zhang, Xinxin
    Liu, Li
    Yao, Yazhou
    Gong, Sha
    Wang, Mengchang
    Xi, Jieying
    Chen, Limei
    Wei, Suhua
    Zhang, Huiyun
    Zhao, Chenyang
    Wang, Huaiyu
    TRIALS, 2020, 21 (01)
  • [2] Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial
    Xinxin Zhang
    Li Liu
    Yazhou Yao
    Sha Gong
    Mengchang Wang
    Jieying Xi
    Limei Chen
    Suhua Wei
    Huiyun Zhang
    Chenyang Zhao
    Huaiyu Wang
    Trials, 21